All In Biotech

Drug Trial Radar · NCT06442241

A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults

A Phase I, Randomized, Observer-Blinded, Parallel-Controlled, Dose Escalation Study to Evaluate the Safety and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell), LYB005, in Healthy Adults Aged 18 Years and Older

Last checked: Nov 19, 2026Latest source record: Mar 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Jul 31, 2024

Primary completion

Dec 30, 2025

Study completion Dec 30, 2025

Sponsor

Sponsor type
Industry
Collaborators
Yantai Patronus Biotech Co., Ltd.
First posted
Jun 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A phase 1, randomized, observer-blinded, parallel-controlled, dose escalation study in Australia will evaluate the safety and immunogenicity of the RSV vaccine candidate LYB005 with or without adjuvant in healthy adults aged 18 years and older.

Conditions

  • Respiratory Syncytial Virus (RSV)
  • RSV Infection

Interventions

  • LYB005 low dose without adjuvantBiological

    Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

  • LYB005 middle dose without adjuvantBiological

    Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

  • LYB005 high dose without adjuvantBiological

    Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

  • LYB005 low dose with adjuvantBiological

    Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

  • LYB005 middle dose with adjuvantBiological

    Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

  • LYB005 high dose with adjuvantBiological

    Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

  • PlaceboBiological

    0.9% sodium chloride injection. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

  • Positive controlBiological

    AREXVY. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Immediate AEs for 30 minutes post-vaccinationTime frame: 30 mins after vaccination
  2. Solicited local and systemic AEs and unsolicited AEsTime frame: Within 7 days after vaccination
  3. Unsolicited AEsTime frame: Within 28 days after vaccination
  4. Clinically significant laboratory abnormalitiesTime frame: Day 4, Day 8, Day 29 and Day 91
  5. Serious adverse events (SAEs) and adverse events of special interest (AESIs)Time frame: Within 6 months after the vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Pty Ltd.

    Melbourne, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.